Financial Disclosure

Mastech Digital to Report Q3 2026 Results on October 30

Image
Mastech Digital to Report Q3 2026 Results on October 30

Pittsburgh – October 19, 2026 -- Mastech Digital (NYSE American: MHH) will publish its third-quarter 2026 financial results before the U.S. market opens on Friday, October 30, 2026.

Management hosts 9:00 a.m. ET call on results day

The company will hold a conference call at 9:00 a.m. Eastern Time on October 30 to review financial performance and operating results for the quarter ended September 30, 2026.

Participants must register in advance to receive dial-in details and a unique PIN. The PIN is exclusive to each registrant and can be used by only one person at a time.

Live webcast and replay available through investor relations site

Mastech will stream a live audio webcast of the call on its investor relations website. A replay will remain available for a limited time after the call.

The release gave no financial figures or guidance ahead of the report.

Ember AI Index: 8% Net Collections Lift, 57% Fewer Denials

Image
Ember AI Index: 8% Net Collections Lift, 57% Fewer Denials

Burlingame, Calif. – October 19, 2026 -- Ember AI reported an 8% lift in net collection rates and a 57% reduction in predicted preventable denials in the inaugural Ember Revenue Integrity Index, an annual report based on performance data from its customer deployments.

The report also records 32% fewer preventable coding issues. Ember AI released it during Healthcare Quality Week.

Pre-submission analysis targets denials before claims go out

Ember AI's platform reviews every patient encounter before claim submission. It looks for documentation gaps, coding inconsistencies, reimbursement risks and payer requirements that could trigger denials or underpayments. The approach contrasts with traditional revenue cycle management, where teams often spend significant resources correcting problems after claims have been submitted.

Lindblad Expeditions to Report Q3 2026 Results on November 3

Image
Lindblad Expeditions to Report Q3 2026 Results on November 3

New York – October 19, 2026 -- Lindblad Expeditions Holdings, Inc. (NASDAQ: LIND) will report its third-quarter 2026 financial results on Tuesday, November 3, 2026, before the market opens. The expedition cruise and adventure travel operator will discuss the figures on an audio conference webcast the same morning.

Lindblad schedules 9:00 a.m. ET webcast for analysts and investors

Management will host the webcast at 9:00 a.m. Eastern Time on November 3. Analysts who want to join the Q&A must use the analyst registration to receive a unique passcode. Dial-in access is also available by phone, with numbers listed by country under meeting ID 416185057.

Earnings release will post to the investor relations site on results day

The earnings release will be available in the investor relations section of the company's website. A replay of the conference will be posted there within 48 hours of its completion.

Hornbeck Offshore Sets Nov. 5 Date for Q3 2026 Results Call

Houston – October 19, 2026 -- Hornbeck Offshore Services (NYSE: HOS) will release its third quarter 2026 financial results on Thursday, November 5, 2026, ahead of a live conference call at 9:00 a.m. Eastern (8:00 a.m. Central).

Hornbeck offers dial-in and webcast access to the November 5 call

The company will host the call for investors and analysts, who can join by telephone or by webcast. Results will be published before the call begins.

Telephone replay stays available through November 19, 2026

Investors who miss the live session can access a telephonic replay until November 19, 2026. A webcast archive will remain available for 60 days after the call through the Investors section of the company's website.

Potter Adams, Executive Vice President and CFO, is the company contact for the announcement. Dennard Lascar Investor Relations, represented by Ken Dennard and Alex Harp, handles investor relations.

PTC to Report FY2026 Results Nov. 4, Drops Guidance Ahead of Schneider Deal

Image
PTC to Report FY2026 Results Nov. 4, Drops Guidance Ahead of Schneider Deal

Boston – October 19, 2026 -- PTC (NASDAQ: PTC) will publish its fiscal 2026 fourth-quarter and full-year results on Wednesday, November 4, after the U.S. stock market closes, but the software maker has stopped earnings calls and guidance because of its pending acquisition by Schneider Electric.

PTC suspends earnings calls and withdraws guidance

PTC is suspending quarterly earnings conference calls. It also no longer provides quarterly or annual guidance. Investors will get no management commentary or forward-looking targets alongside the November 4 figures.

The company ties both changes directly to the pending transaction.

Schneider Electric agreement dates to October 5

PTC announced on October 5, 2026 that it had entered into a definitive agreement to be acquired by Schneider Electric. The source material gives no purchase price, closing timeline or regulatory conditions for the deal.

Huhtamaki to Report Q3 2026 Results on October 29

Helsinki -- Huhtamäki Oyj will publish its Q3 2026 interim report on Thursday, October 19, 2026, at approximately 8:30 EET, the company said in a release dated October 19.

Results presentation material goes live on the investor site at release

The interim report and the accompanying results presentation will be available on Huhtamaki's investor relations website once published.

CEO Ralf K. Wunderlich and CFO Thomas Geust present at 9:30 EET

Huhtamaki will hold a combined audiocast and teleconference on the same day at 9:30 EET, one hour after the report. CEO and President Ralf K. Wunderlich and CFO Thomas Geust will present the results, followed by a Q&A session. The event will be held in English and can be followed in real time.

Nutex Health to Report Q3 Results Nov. 5, Hold Call Nov. 6

Houston – – October 19, 2026 -- Nutex Health, Inc. (NASDAQ: NUTX) will file its Form 10-Q for the third fiscal quarter ended Sept. 30, 2026, on Thursday, Nov. 5, 2026, after the market close.

The company will issue a press release summarizing the quarterly financial results the same day.

Nutex Health schedules Nov. 6 earnings call for 9:30 a.m. CT

Management will discuss financial performance and provide a business update on Friday, Nov. 6, 2026. Participants can join through an operator using the dial-in numbers 1-877-407-9208 or 1-201-493-6784, or through an online Call meTM link that goes live 15 minutes before the start. A transcript and recording will be posted afterward in the "Investor Materials" section of the company website.

SMB CEO Confidence Falls 3.4 Points to 80.8 as Costs Squeeze Margins

Image
SMB CEO Confidence Falls 3.4 Points to 80.8 as Costs Squeeze Margins

San Diego – October 19, 2026 -- The Vistage CEO Confidence Index fell 3.4 points to 80.8 in Q3 2026 from 84.2 in the prior quarter, marking the third consecutive quarterly decline in small and midsize business (SMB) CEO sentiment.

Expectations for the year ahead dropped the most. Only 19% of CEOs expect the U.S. economy to improve over the next year, down 10 percentage points from last quarter and 13 points below Q3 2025. A further 34% expect conditions to worsen, up 8 points.

Revenue hopes hold at 62%, but profit expectations lag at 47%

Some 62% of CEOs expect higher revenue, down 2 points from last quarter. Only 47% expect higher profit, as rising costs erode margins. Of those surveyed, 36% plan to increase fixed investments over the next year, down from 38% in Q2. Another 46% say U.S. economic conditions have worsened versus last year, while 14% say they have improved, down 5 points.

Capricor Cash Falls to $237.9M After FDA Panel Votes Against Drug

Image
Capricor Cash Falls to $237.9M After FDA Panel Votes Against Drug

San Diego – October 19, 2026 -- Capricor Therapeutics (NASDAQ: CAPR) ended the second quarter with about $237.9 million in cash, cash equivalents and marketable securities, down from about $318.1 million at Dec. 31, 2025. The decline came as an FDA advisory committee voted 9 against and 3 in favor on whether evidence shows Deramiocel is effective for cardiomyopathy in Duchenne muscular dystrophy (DMD) patients.

Advisory panel vote is non-binding and limited to cardiomyopathy

The Cellular, Tissue and Gene Therapies Advisory Committee voted on July 29, 2026. Capricor says the panel was not asked to vote on the HOPE-3 primary endpoint or on overall benefit-risk. In a separate discussion of upper limb function, the committee's feedback was directionally supportive of the HOPE-3 evidence, according to the company. The recommendation is advisory and non-binding, and the Biologics License Application (BLA) remains under active FDA review.

Boots Group Seeks Noteholder Consent Ahead of Wittington-Fairfax Deal

London – October 19, 2026 -- Boots Group Finco L.P. and The Boots Group Luxco S.à r.l. have launched a consent solicitation covering €650 million of 5.375% and £375 million of 7.375% senior secured notes due 2032, offering holders a cash fee of 2.50 per 1,000 of principal for backing indenture changes tied to a pending change of ownership.

Wittington and Fairfax funds agree to acquire Boots Group parent on October 7

Oak UK Bidco Limited, owned directly or indirectly by funds linked to Wittington Investments, Limited, together with funds linked to Fairfax Financial Holdings Limited, signed a share purchase agreement on October 7, 2026. Under it, the buyer will acquire all issued and outstanding ordinary shares of Blazing Star Boots Superco (Jersey) Limited from The Boots Group Limited. Completion is expected in the first half of 2027, though the agreement allows that date to be extended.